FibroGen (FGEN) Misses Q2 EPS by 100c

FibroGen (NASDAQ: FGEN) reported Q2 EPS of ($1.45), $1.00 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $24.4 million versus the consensus estimate of $71.38 million.

For earnings history and earnings-related data on FibroGen (FGEN) click here.

You May Also Be Interested In

• H&R Block (HRB) Tops Q4 EPS by 7c, Offers Guidance
• Hour Loop, Inc. (HOUR) Reports Q2 EPS of $0.03
• Kyverna Therapeutics, Inc. (KYTX) Tops Q2 EPS by 45c